File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Excellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol

TitleExcellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol
Authors
KeywordsAML
Childhood leukemia
MRC AML12
Pediatrics
Prognostic factors
Issue Date2021
PublisherElsevier Inc. The Journal's web site is located at http://www.clinical-lymphoma-myeloma-leukemia.com/
Citation
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21 n. 3, p. e290-e300 How to Cite?
AbstractPurpose: To determine the prognostic factors in pediatric patients with acute myeloid leukemia (AML) and to assess whether their outcomes have improved over time. Patients and Methods: Sixty-two patients with AML excluding acute promyelocytic leukemia were retrospectively analyzed. Patients in the earlier cohort (n = 36) were treated on the Medical Research Council (MRC) AML12 protocol, whereas those in the recent cohort (n = 26) were treated on the Malaysia–Singapore AML protocol (MASPORE 2006), which differed in terms of risk group stratification, cumulative anthracycline dose, and timing of hematopoietic stem-cell transplantation for high-risk patients. Results: Significant improvements in 10-year overall survival and event-free survival were observed in patients treated with the recent MASPORE 2006 protocol compared to the earlier MRC AML12 protocol (overall survival: 88.0% ± 6.5% vs 50.1% ± 8.6%, P = .002; event-free survival: 72.1% ± 9.0 vs 50.1% ± 8.6%, P = .045). In univariate analysis, patients in the recent cohort had significantly lower intensive care unit admission rate (11.5% vs 47.2%, P = .005) and numerically lower relapse rate (26.9% vs 50.0%, P = .068) compared to the earlier cohort. Multivariate analysis showed that treatment protocol was the only independent predictive factor for overall survival (hazard ratio = 0.21; 95% confidence interval, 0.06-0.73, P = .014). Conclusion: Outcomes of pediatric AML patients have improved over time. The more recent MASPORE 2006 protocol led to significant improvement in long-term survival rates and reduction in intensive care unit admission rate.
Persistent Identifierhttp://hdl.handle.net/10722/305869
ISSN
2023 Impact Factor: 2.7
2023 SCImago Journal Rankings: 0.548
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSutiman, N-
dc.contributor.authorNwe, MS-
dc.contributor.authorLai, EEN-
dc.contributor.authorLee, DK-
dc.contributor.authorChan, MY-
dc.contributor.authorYeoh, AEJ-
dc.contributor.authorSoh, SY-
dc.contributor.authorLeung, W-
dc.contributor.authorTan, AM-
dc.date.accessioned2021-10-20T10:15:29Z-
dc.date.available2021-10-20T10:15:29Z-
dc.date.issued2021-
dc.identifier.citationClinical Lymphoma, Myeloma & Leukemia, 2021, v. 21 n. 3, p. e290-e300-
dc.identifier.issn2152-2650-
dc.identifier.urihttp://hdl.handle.net/10722/305869-
dc.description.abstractPurpose: To determine the prognostic factors in pediatric patients with acute myeloid leukemia (AML) and to assess whether their outcomes have improved over time. Patients and Methods: Sixty-two patients with AML excluding acute promyelocytic leukemia were retrospectively analyzed. Patients in the earlier cohort (n = 36) were treated on the Medical Research Council (MRC) AML12 protocol, whereas those in the recent cohort (n = 26) were treated on the Malaysia–Singapore AML protocol (MASPORE 2006), which differed in terms of risk group stratification, cumulative anthracycline dose, and timing of hematopoietic stem-cell transplantation for high-risk patients. Results: Significant improvements in 10-year overall survival and event-free survival were observed in patients treated with the recent MASPORE 2006 protocol compared to the earlier MRC AML12 protocol (overall survival: 88.0% ± 6.5% vs 50.1% ± 8.6%, P = .002; event-free survival: 72.1% ± 9.0 vs 50.1% ± 8.6%, P = .045). In univariate analysis, patients in the recent cohort had significantly lower intensive care unit admission rate (11.5% vs 47.2%, P = .005) and numerically lower relapse rate (26.9% vs 50.0%, P = .068) compared to the earlier cohort. Multivariate analysis showed that treatment protocol was the only independent predictive factor for overall survival (hazard ratio = 0.21; 95% confidence interval, 0.06-0.73, P = .014). Conclusion: Outcomes of pediatric AML patients have improved over time. The more recent MASPORE 2006 protocol led to significant improvement in long-term survival rates and reduction in intensive care unit admission rate.-
dc.languageeng-
dc.publisherElsevier Inc. The Journal's web site is located at http://www.clinical-lymphoma-myeloma-leukemia.com/-
dc.relation.ispartofClinical Lymphoma, Myeloma & Leukemia-
dc.subjectAML-
dc.subjectChildhood leukemia-
dc.subjectMRC AML12-
dc.subjectPediatrics-
dc.subjectPrognostic factors-
dc.titleExcellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol-
dc.typeArticle-
dc.identifier.emailLeung, W: leungwhf@hku.hk-
dc.identifier.authorityLeung, W=rp02760-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.clml.2020.11.016-
dc.identifier.pmid33384264-
dc.identifier.scopuseid_2-s2.0-85098659822-
dc.identifier.hkuros328053-
dc.identifier.volume21-
dc.identifier.issue3-
dc.identifier.spagee290-
dc.identifier.epagee300-
dc.identifier.isiWOS:000621051300009-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats